Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Androgen deprivation therapy is a mainstay for the treatment of advanced prostate cancer. Hormonal therapy commonly consists of injection of gonadotropin hormone-releasing hormone agonists. Based on the need for improved convenience of administration, a novel formulation of leuprolide acetate (Eligard; Atrix Laboratories Inc. & Sanofi Aventis) which incorporates a mixture of selected polymers and solvents to achieve sustained drug delivery after subcutaneous injection, was developed. The US Food and Drug Administration has approved 1-, 3-, 4- and 6-month formulations of leuprolide acetate. In clinical trials, leuprolide acetate achieves sustained suppression of serum testosterone to castration levels (< or =50 ng/dl). The adverse-event profile is consistent with the effects of testosterone suppression. This novel delivery system in addition to the availability of a 6-month formulation of leuprolide acetate, offers patients the option of a convenient twice-yearly injection schedule.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737140.5.4.605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate.
Ann Pediatr Endocrinol Metab
August 2025
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Purpose: Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.
View Article and Find Full Text PDFCommentary on "Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate".
Ann Pediatr Endocrinol Metab
August 2025
Department of Pediatrics, Inje University Sanggye Paik Hospital, Inje University School of Medicine, Seoul, Korea.
Late-onset Leber's hereditary optic neuropathy and antiandrogens for prostate cancer: is there a causative link?
Front Neurol
August 2025
Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Introduction: Leber's hereditary optic neuropathy (LHON) is a maternally inherited condition due to mitochondrial DNA (mtDNA) mutations usually affecting young men within their thirties, while women seem protected by estrogens with a female-to-male ratio of 1:3. Late-onset cases (over 40 years of age) are usually associated to toxic exposure to tobacco smoke or drugs causing mitochondrial dysfunction.
Results: We describe two cases of LHON remarkable for their late onset (> 60 years) in the absence of classic toxic factors.
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis.
EClinicalMedicine
September 2025
START Carolinas/Carolina Urologic Research Center, 823 82 Parkway, Suite B, Myrtle Beach, SC, USA.
Background: Enzalutamide was approved for high-risk biochemically recurrent (hrBCR) prostate cancer based on the EMBARK trial (NCT02319837; 17 December 2014-31 January 2023). In EMBARK, treatment was suspended at week 37 if prostate-specific antigen (PSA) was <0.2 ng/mL and reinstated if PSA rose to ≥2.
View Article and Find Full Text PDF